Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Vijaya Diagnost.
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 121 | 121 | 139 | 133 | 155 | 156 | 183 | 169 | 173 | 188 | 202 | 205 | 219 |
| Expenses + | 72 | 73 | 82 | 80 | 92 | 95 | 107 | 102 | 104 | 115 | 120 | 119 | 124 |
| Operating Profit | 49 | 48 | 57 | 52 | 63 | 61 | 76 | 67 | 69 | 74 | 82 | 86 | 96 |
| OPM % | 41% | 40% | 41% | 39% | 41% | 39% | 42% | 40% | 40% | 39% | 41% | 42% | 44% |
| Other Income + | 5 | 6 | 7 | 3 | 3 | 4 | 5 | 5 | 5 | 7 | 6 | 5 | 2 |
| Interest | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 9 | 9 |
| Depreciation | 11 | 12 | 14 | 15 | 16 | 17 | 17 | 18 | 19 | 21 | 22 | 24 | 24 |
| Profit before tax | 36 | 35 | 45 | 35 | 44 | 42 | 57 | 47 | 47 | 52 | 58 | 58 | 64 |
| Tax % | 24% | 26% | 25% | 25% | 23% | 25% | 26% | 24% | 26% | 26% | 25% | 26% | 25% |
| Net Profit + | 28 | 26 | 34 | 26 | 34 | 32 | 42 | 35 | 35 | 39 | 43 | 43 | 48 |
| EPS in Rs | 2.69 | 2.57 | 3.26 | 2.53 | 3.27 | 3.06 | 4.10 | 3.43 | 3.40 | 3.76 | 4.21 | 4.20 | 4.66 |
Financials of Vijaya Diagnost.
Annual income statement trend
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 251 | 293 | 339 | 377 | 462 | 459 | 548 | 681 | 814 |
| Expenses + | 171 | 184 | 206 | 211 | 259 | 277 | 327 | 408 | 477 |
| Operating Profit | 80 | 108 | 133 | 166 | 204 | 182 | 221 | 273 | 337 |
| OPM % | 32% | 37% | 39% | 44% | 44% | 40% | 40% | 40% | 41% |
| Other Income + | 7 | 10 | 15 | 12 | 13 | 14 | 19 | 17 | 21 |
| Interest | 5 | 14 | 15 | 15 | 16 | 21 | 24 | 27 | 33 |
| Depreciation | 26 | 40 | 49 | 50 | 53 | 62 | 57 | 71 | 92 |
| Profit before tax | 55 | 65 | 83 | 112 | 147 | 114 | 159 | 193 | 233 |
| Tax % | 37% | 29% | 25% | 24% | 25% | 25% | 25% | 26% | 26% |
| Net Profit + | 35 | 46 | 63 | 85 | 111 | 85 | 120 | 144 | 173 |
| EPS in Rs | 77.44 | 101.29 | 138.00 | 18.64 | 10.76 | 8.29 | 11.61 | 13.94 | 16.81 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 9% | 12% | 9% | 14% | 12% |
Financials of Vijaya Diagnost.
Capital structure and asset base
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 157 | 203 | 270 | 354 | 458 | 535 | 647 | 785 | 947 |
| Borrowings + | 33 | 146 | 161 | 141 | 183 | 248 | 259 | 320 | 423 |
| Other Liabilities + | 39 | 53 | 46 | 41 | 62 | 61 | 66 | 158 | 127 |
| Total Liabilities | 234 | 406 | 482 | 541 | 713 | 853 | 983 | 1,274 | 1,507 |
| Fixed Assets + | 119 | 259 | 272 | 268 | 370 | 524 | 742 | 865 | 1,070 |
| CWIP | 3 | 3 | 10 | 9 | 34 | 28 | 9 | 70 | 34 |
| Investments | 73 | 69 | 55 | 28 | 54 | 139 | 109 | 185 | 228 |
| Other Assets + | 39 | 76 | 146 | 236 | 255 | 163 | 123 | 154 | 174 |
| Total Assets | 234 | 406 | 482 | 541 | 713 | 853 | 983 | 1,274 | 1,507 |
Financials of Vijaya Diagnost.
Operating, investing and financing cash movement
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 62 | 91 | 106 | 130 | 158 | 165 | 183 | 224 | 271 |
| Cash from Investing Activity + | -98 | -90 | -31 | -130 | -123 | -110 | -141 | -182 | -174 |
| Cash from Financing Activity + | -8 | -7 | -30 | -49 | -31 | -42 | -45 | -52 | -69 |
| Net Cash Flow | -44 | -6 | 46 | -49 | 4 | 13 | -2 | -9 | 27 |
| Free Cash Flow | 32 | 31 | 69 | 98 | 37 | 40 | 99 | 132 | 91 |
| CFO/OP | 103% | 101% | 98% | 97% | 97% | 105% | 98% | 97% | 96% |
Financials of Vijaya Diagnost.
Working capital efficiency and return ratios
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12 | 11 | 9 | 6 | 8 | 8 | 11 | 8 | 9 |
| Inventory Days | 24 | 20 | 23 | 17 | 22 | 13 | 29 | 21 | 19 |
| Days Payable | 176 | 196 | 180 | 142 | 110 | 172 | 184 | 143 | 145 |
| Cash Conversion Cycle | -140 | -165 | -149 | -118 | -81 | -152 | -144 | -114 | -117 |
| Working Capital Days | -41 | -51 | -49 | -26 | -34 | -36 | -29 | -48 | 65 |
| ROCE % | 28% | 23% | 27% | 28% | 18% | 20% | 21% | 21% |
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
July monthly revenue stood at INR 150+ crores, indicating strong growth momentum. Key concall takeaways from Health X Platform Ltd's Q1 FY27 earnings call…
Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase. Key concall takeaways from Shalby Ltd's Q1 FY27 earnings call — and how…